Siemens Healthcare Diagnostics Inc. Alan Haley   
Regulatory Clinical Affairs Specialist 500 GBC Drive   
Newark, Delaware 19714-6101

Re: K171771 Trade/Device Name: ADVIA Chemistry Enzymatic Hemoglobin A1c (A1c_E) Assay Regulation Number: 21 CFR 862.1373 Regulation Name: Hemoglobin A1c Test System Regulatory Class: Class II Product Code: PDJ, LCP Dated: October 16, 2017 Received: October 17, 2017

Dear Alan Haley:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR

Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Kellie B. Kelm -S

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

Device Name ADVIA $^ \mathrm { \textregistered }$ Chemistry Enzymatic Hemoglobin A1c (A1c_E) Assay

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# SIEMENS

# 510(k) Summary – K171771

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of Safe Medical Device Act of 1990 and 21 CFR 807.92.

# 1. Submitter

<table><tr><td>Company</td><td>Siemens Healthcare Diagnostics Inc.</td></tr><tr><td>Address</td><td>500 GBC Drive</td></tr><tr><td></td><td>Newark, DE 19702</td></tr><tr><td>Contact</td><td>Alan Haley</td></tr><tr><td>Telephone</td><td>302.631.9883</td></tr><tr><td>Fax</td><td>302.631.6299</td></tr><tr><td>Date of Preparation</td><td>November 29, 2017</td></tr></table>

# 2. Device Information

<table><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=2>ADVIA® Chemistry Enzymatic Hemoglobin A1c (A1c_ E) Assay</td></tr><tr><td rowspan=1 colspan=1>Common Name</td><td rowspan=1 colspan=1>Hemoglobin A1c Test System</td><td rowspan=1 colspan=1>Assay, Glycosylated Hemoglobin</td></tr><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Hemoglobin A1c Test System</td><td rowspan=1 colspan=1>Glycosylated hemoglobin assay</td></tr><tr><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>21 CFR 862.1373</td><td rowspan=1 colspan=1>21 CFR 864.7470</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>PDJ</td><td rowspan=1 colspan=1>LCP</td></tr><tr><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>Clinical Chemistry</td><td rowspan=1 colspan=1>Hematology</td></tr></table>

# 3. Identification of Predicate

<table><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>ARCHITECT Hemoglobin A1C</td></tr><tr><td rowspan=1 colspan=1>510(k) Submitter</td><td rowspan=1 colspan=1>Abbott Laboratories Diagnostics Division</td></tr><tr><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>K130255</td></tr><tr><td rowspan=1 colspan=1>Clearance Date</td><td rowspan=1 colspan=1>February 28, 2014</td></tr></table>

# 4. Device Description

The ADVIA $\textsuperscript { \textregistered }$ Chemistry Enzymatic Hemoglobin A1c (A1c_E) assay measures hemoglobin A1c in human anticoagulated whole blood and hemolysate. The assay consists of three reagents (R1, R2, and Pretreatment). These reagents are liquid and are ready to use. The assay offers both an automated and a manual application. The automated application (A1c_E) lyses the anticoagulated whole blood specimen on the system for the automated application (A1c_E). Samples may also be lysed manually using the ADVIA $\textsuperscript { \textregistered }$ Chemistry A1c_E pretreatment solution to obtain hemolysate for the manual application (A1c_EM). The two applications yield the same results.

# 5. Intended Use Statement

The ADVIA $\textsuperscript { \textregistered }$ Chemistry Enzymatic Hemoglobin A1c (A1c_E) assay is an in vitro diagnostic assay for the quantitative determination of mmol/mol HbA1c (IFCC) and $\%$ HbA1c (DCCT/NGSP) in human anticoagulated venous whole blood and hemolysate for use on the ADVIA $\textsuperscript { \textregistered }$ Chemistry systems. Measurement of Hemoglobin A1c is used as an aid in the diagnosis and monitoring of long-term blood glucose control in patients with diabetes mellitus, and as an aid in the identification of patients at risk for developing diabetes mellitus.

# 6. Technological Characteristics

# (a) Similarities and Differences

<table><tr><td colspan="1" rowspan="1">DeviceCharacteristic</td><td colspan="1" rowspan="1">Proposed DeviceADVIA® ChemistryEnzymatic Hemoglobin A1c(A1c_E) Assay</td><td colspan="1" rowspan="1">Predicate DeviceAbbott ArchitectHemoglobin A1c(K130255)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The ADVIA® ChemistryEnzymatic Hemoglobin A1c(A1c_E) assay is an in vitrodiagnostic assay for thequantitative determination ofmmol/mol HbA1c (IFCC) and %HbA1c (DCCT/NGSP) in humananticoagulated venous wholeblood and hemolysate for useon the ADVIA® Chemistrysystems. Measurement ofHemoglobin A1c is used as anaid in the diagnosis andmonitoring of long-term bloodglucose control in patients withdiabetes mellitus, and as an aidin the identification of patients atrisk for developing diabetesmellitus.</td><td colspan="1" rowspan="1">The Hemoglobin A1c assay isused in clinical laboratories forthe quantitative in vitromeasurement of percenthemoglobin A1c (NGSP) orHbA1c fraction mmol/mol(IFCC) in human whole bloodand hemolysate on theARCHITET c 8000 System.Hemoglobin A1c measurementsare used as an aid in thediagnosis of diabetes mellitus,as an aid to identify patientswho may be at risk fordeveloping diabetes mellitus,and for the monitoring of long-term blood glucose control inindividuals with diabetesmellitus.</td></tr><tr><td colspan="1" rowspan="1">Type of Test</td><td colspan="1" rowspan="1">Quantitative, enzymatic</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measuring Range</td><td colspan="1" rowspan="1">3.8 to 14.0% HbA1c(DCCT/NGSP)18.03 -129.50 mmol/mol HbA1c(IFCC)</td><td colspan="1" rowspan="1">4.0 to 14.0% HbA1c(DCCT/NGSP)20.22-129.50 mmol/mol HbA1c(IFCC)</td></tr><tr><td colspan="1" rowspan="1">Specimen Types</td><td colspan="1" rowspan="1">Whole blood and Hemolysate</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">AnticoagulantTypes</td><td colspan="1" rowspan="1">•  Dipotassium EDTA•   Lithium HeparinSodium Fluoride/DisodiumEDTATripotassium EDTA</td><td colspan="1" rowspan="1">•  Dipotassium EDTALithium HeparinSodium Fluoride/DisodiumEDTATripotassium EDTASodium Heparin</td></tr><tr><td colspan="1" rowspan="1">Standardizationand Certification</td><td colspan="1" rowspan="1">Assay standardization istraceable to InternationalFederation of Clinical Chemistry(IFCC) reference calibrators.Assay is certified with theNational GlycohemoglobinStandardization Program(NGSP). The NGSP certificationexpires in one year.</td><td colspan="1" rowspan="1">The Architect HbA1c assaystandardization is traceable tothe International Federation ofClinical Chemistry (IFCC)reference calibrators. TheArchitect HbA1c assay is NGSPcertified. The NGSP certificationexpires in one year.</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">ADVIA® 1800 ClinicalChemistry System</td><td colspan="1" rowspan="1">ARCHITECT c 8000 System(clinical chemistry analyzer)</td></tr><tr><td colspan="1" rowspan="1">Reporting Units</td><td colspan="1" rowspan="1">% HbA1c NGSP/DCCT andmmol/mol IFCC</td><td colspan="1" rowspan="1">% HbA1c NGSP/DCCT andmmol/mol IFCC</td></tr></table>

# (b) Non-Clinical Performance Evaluation

(i) Method Comparison

Method comparison testing was performed in accordance with CLSI EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition.

One hundred sixty-three (163) human whole blood samples with values spanning the assay range were tested on the ADVIA $\textsuperscript { \textregistered }$ 1800 Clinical Chemistry System. Testing was performed in both automated (A1c_E) and manual (A1c_EM) modes.

Results on the ADVIA® 1800 were compared to results from NGSP reference method testing performed at an NGSP primary reference laboratory. Sample distribution is shown in Tables A and B. Slope and Y-intercept results were generated with both Passing-Bablok regression and Deming analysis. Correlation (r) values are Pearson correlation coefficients. Results are presented in Tables C, D, E, and F.

Table A. Method Comparison Sample Distribution, Automated (Whole Blood)   

<table><tr><td rowspan=1 colspan=1>Range of Results(%HbA1c)</td><td rowspan=1 colspan=1>Percentage ofSamples</td><td rowspan=1 colspan=1>Number ofSamples</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>7%</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>5 - 6</td><td rowspan=1 colspan=1>14%</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>6 - 6.5</td><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>6.5 - 7</td><td rowspan=1 colspan=1>18%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>7 - 8</td><td rowspan=1 colspan=1>12%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=1 colspan=1>8-9</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>&gt;9</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>163</td></tr></table>

# SIEMENS

Table B. Method Comparison Sample Distribution, Manual (Hemolysate)   

<table><tr><td rowspan=1 colspan=1>Range of Results(%HbA1c)</td><td rowspan=1 colspan=1>Percentage ofSamples</td><td rowspan=1 colspan=1>Number ofSamples</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>5 - 6</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>6 - 6.5</td><td rowspan=1 colspan=1>21%</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>6.5 - 7</td><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=1 colspan=1>7 - 8</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>8-9</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>&gt;9</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>163</td></tr></table>

Table C. Method Comparison, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>Option</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-int.[95% CI]</td><td rowspan=1 colspan=1>SampleRange</td></tr><tr><td rowspan=2 colspan=1>NGSP(%HbA1c)</td><td rowspan=1 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.019[1.000 to 1.037]</td><td rowspan=1 colspan=1>-0.110[-0.248 to 0.010]</td><td rowspan=1 colspan=1>3.80 to13.60</td></tr><tr><td rowspan=1 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.022[1.004 to 1.041]</td><td rowspan=1 colspan=1>-0.132[-0.280 to -0.019]</td><td rowspan=1 colspan=1>3.80 to13.60</td></tr><tr><td rowspan=2 colspan=1>IFCC(mmol/molHbA1c</td><td rowspan=1 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.019[1.000 to 1.037]</td><td rowspan=1 colspan=1>-0.761[-1.848 to 0.109]</td><td rowspan=1 colspan=1>18.01 to125.14</td></tr><tr><td rowspan=1 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.022[1.004 to 1.041]</td><td rowspan=1 colspan=1>-0.923[-2.092 to -0.109]</td><td rowspan=1 colspan=1>18.01 to125.14</td></tr></table>

Table D. Bias Estimations, Passing-Bablok   

<table><tr><td rowspan=2 colspan=1>%HbA1c</td><td rowspan=1 colspan=2>Automated(Whole Blood)</td><td rowspan=1 colspan=2>Manual(Hemolysate)</td></tr><tr><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>-0.01</td><td rowspan=1 colspan=1>-0.20</td><td rowspan=1 colspan=1>-0.02</td><td rowspan=1 colspan=1>-0.40</td></tr><tr><td rowspan=1 colspan=1>6.50</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.15</td></tr><tr><td rowspan=1 colspan=1>8.00</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>12.00</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.08</td></tr></table>

Table E. Method Comparison, Deming   

<table><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>Option</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-int.[95% CI]</td><td rowspan=1 colspan=1>SampleRange</td></tr><tr><td rowspan=2 colspan=1>NGSP(%HbA1c)</td><td rowspan=1 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.020[1.004 to 1.036]</td><td rowspan=1 colspan=1>-0.120[-0.265 to -0.006]</td><td rowspan=1 colspan=1>3.80 to13.60</td></tr><tr><td rowspan=1 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.027[1.012 to 1.042]</td><td rowspan=1 colspan=1>-0.176[-0.280 to -0.072]</td><td rowspan=1 colspan=1>3.80 to13.60</td></tr><tr><td rowspan=2 colspan=1>IFCC(mmol/molHbA1c</td><td rowspan=1 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>1.020[1.004 to 1.036]</td><td rowspan=1 colspan=1>-0.840[-1.738 to 0.058]</td><td rowspan=1 colspan=1>18.01 to125.14</td></tr><tr><td rowspan=1 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.027[1.012 to 1.042]</td><td rowspan=1 colspan=1>-1.290[-2.098 to -0.438]</td><td rowspan=1 colspan=1>18.01 to125.14</td></tr></table>

Table F. Bias Estimations, Deming   

<table><tr><td rowspan=2 colspan=1>%HbA1c</td><td rowspan=1 colspan=2>Automated(Whole Blood)</td><td rowspan=1 colspan=2>Manual(Hemolysate)</td></tr><tr><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>-0.02</td><td rowspan=1 colspan=1>-0.40</td><td rowspan=1 colspan=1>-0.04</td><td rowspan=1 colspan=1>-0.80</td></tr><tr><td rowspan=1 colspan=1>6.50</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>8.00</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>12.00</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>1.25</td></tr></table>

(ii) Precision

Precision testing was performed in accordance with CLSI EP05-A3, Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline – Third Edition.

Samples consisted of two (2) commercial quality controls and four whole blood patient pools with target values of $5 . 0 \%$ HbA1c, $6 . 5 \%$ HbA1c, $8 . 0 \%$ HbA1c, and $1 2 . 0 \%$ HbA1c. Whole blood pools were aliquoted and frozen prior to the start of the study. Each testing day, whole blood pool aliquots were thawed. QC materials were handled according to manufacturer’s instructions.

Testing was performed over twenty (20) days, two (2) runs per day (with a minimum of 2 hours in between), a single test from two (2) independent cups were analyzed for each test material. Testing was performed using three (3) reagent lots and three (3) ADVIA $\textcircled{8}$ 1800 instruments for a total of nine (9) sets of data. Testing was performed in both automatic and manual modes. Two calibrations were performed over the duration of the study. Data were analyzed using Analysis of Variance (ANOVA), consistent with the recommendations of CLSI EP05-A3. Results are presented in Tables I, J, K, and L.

Table I. Precision, All Instruments, Automated (Whole Blood), NGSP Units (%HbA1c)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeat-bility</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SAMPLE</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>4.49</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>9.05</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>5.36</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>6.56</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>8.01</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>12.11</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.0</td></tr></table>

Table J. Precision, All Instruments, Automated (Whole Blood), IFCC Units (mmol/mol)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeat-ability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SAMPLE</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>25.56</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>75.18</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>35.17</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.69</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>48.40</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>64.14</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>108.90</td><td rowspan=1 colspan=1>0.49</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.27</td><td rowspan=1 colspan=1>1.2</td></tr></table>

# SIEMENS

Table K. Precision, All Instruments, Manual (Hemolysate), NGSP Units (%HbA1c)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeat- ability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SAMPLE</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>4.72</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>9.27</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>5.29</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>6.48</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>7.91</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>12.03</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.0</td></tr></table>

Table L. Precision, All Instruments, Manual (Hemolysate), IFCC Units (%HbA1c)   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>Repeat-aility</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SAMPLE</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>28.06</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>77.78</td><td rowspan=1 colspan=1>0.37</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>34.31</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.59</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>47.34</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.66</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>62.96</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>107.94</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.43</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>1.2</td></tr></table>

# (iii) Total Error at Decision Levels

The bias estimation values determined in the method comparison study and precision estimates determined in the precision study were used to determine the total error at each of the levels listed in Tables M and N. Total error was calculated as follows:

$$
\% T A E = | \% B i a s | + 1 . 9 6 \times \% C V \times \left( 1 + \frac { \% B i a s } { 1 0 0 } \right)
$$

Table M. Total Error Summary, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>Option</td><td rowspan=1 colspan=1>%HbA1cDecision Level</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=4 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.20</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>2.52</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>2.24</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>2.44</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>2.88</td></tr><tr><td rowspan=4 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.40</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>2.38</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>1.97</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>2.33</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.08</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>3.06</td></tr></table>

Table N. Total Error Summary, Deming   

<table><tr><td rowspan=1 colspan=1>Option</td><td rowspan=1 colspan=1>%HbA1cDecision Level</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=4 colspan=1>Automated(Whole Blood)</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.40</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>2.72</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>1.07</td><td rowspan=1 colspan=1>2.24</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>2.44</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>2.88</td></tr><tr><td rowspan=4 colspan=1>Manual(Hemolysate)</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.80</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>2.78</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>1.81</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>2.33</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.25</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>3.22</td></tr></table>

# (iv) Endogenous Interference

Testing to determine the interference bias of various endogenous interferents on the ADVIA A1c_E Assay was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition. The effect of each interferent was evaluated using a paired difference analysis. Three replicates were tested at each of two HbA1c levels: $6 . 5 \% \pm 1 . 0 \%$ and $8 . 0 \% \pm 1 . 0 \%$ . No significant interference (greater than $\pm 5 . 0 \%$ ) was observed for the potential interferents at the concentrations listed in Table O.

Table O. Endogenous Interference   

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Interferent Level</td><td rowspan=1 colspan=1>ApproximateHbA1c Level</td></tr><tr><td rowspan=2 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>3.0 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>3.0 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>10 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Total Protein</td><td rowspan=1 colspan=1>22 g/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>22 g/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>2000mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>2000mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Urea</td><td rowspan=1 colspan=1>667mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>667 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Vitamin E</td><td rowspan=1 colspan=1>8.6 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>8.6 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr></table>

# (v) Exogenous Interference

Testing to determine the interference bias of various exogenous interferents on the ADVIA A1c_E Assay was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition. The effect of each interferent was evaluated using a paired difference analysis. Three replicates were tested at each of two HbA1c levels: $6 . 5 \% \pm 1 . 0 \%$ and $8 . 0 \% \pm 1 . 0 \%$ . No significant (bias greater than $\pm 5 . 0 \%$ ) interference was observed for the potential interferents at the concentrations listed in Table P.

# SIEMENS

Table P. Exogenous Interference   

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Interferent Level</td><td rowspan=1 colspan=1>ApproximateHbA1c Level</td></tr><tr><td rowspan=2 colspan=1>Acarbose</td><td rowspan=1 colspan=1>50 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>50 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200 μg/mL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>200 μg/mL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Acetylsalicylate</td><td rowspan=1 colspan=1>50.0 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>50.0 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Atorvastatin</td><td rowspan=1 colspan=1>600 μg Eq/L</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>600 μg Eq/L</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Captopril</td><td rowspan=1 colspan=1>0.5 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>0.5 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Chlorpropamide</td><td rowspan=1 colspan=1>74.7 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>74.7 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Cyanate</td><td rowspan=1 colspan=1>64.8 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>64.8 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Furosemide</td><td rowspan=1 colspan=1>6.0 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>6.0 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Gemfibrozil</td><td rowspan=1 colspan=1>7.5 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>7.5 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Glucose</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>0.5 mg/mL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>0.5 mg/mL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Insulin</td><td rowspan=1 colspan=1>450 μU/mL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>450 μU/mL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>1000 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Losartan</td><td rowspan=1 colspan=1>5 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>5 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Metamizole</td><td rowspan=1 colspan=1>90 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>90 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Metformin</td><td rowspan=1 colspan=1>5.1 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>5.1 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>N-acetylcysteine</td><td rowspan=1 colspan=1>5 mmol/L</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>5 mmol/L</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Nicotinic Acid</td><td rowspan=1 colspan=1>61 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>61 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Propranolol</td><td rowspan=1 colspan=1>0.2 mg/dL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>0.2 mg/dL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Repaglinide</td><td rowspan=1 colspan=1>60 ng/mL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>60 ng/mL</td><td rowspan=1 colspan=1>~8.0 %</td></tr><tr><td rowspan=2 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>200 IU/mL</td><td rowspan=1 colspan=1>~6.5 %</td></tr><tr><td rowspan=1 colspan=1>200 IU/mL</td><td rowspan=1 colspan=1>~8.0 %</td></tr></table>

# SIEMENS

(vi) Hemoglobin Derivative Interference

Hemoglobin derivative interference was determined per CLSI EP7‑A2. No significant interference was observed for HbA0, HbA1a, HbA1b and for the hemoglobin derivatives listed below.

Acetylated Hemoglobin with $\geq 5 0 { \mathrm { ~ m g / d L } }$ of acetylsalicylic acid Carbamylated Hemoglobin with $\geq$ 10 mmol/L of Cyanate Labile Hemoglobin with $\geq 1 0 0 0 \mathrm { m g / d L }$ of Glucose

# (vii) Hemoglobin Variant Interference

Interference testing to determine the effect of hemoglobin variants on the ADVIA A1c_E Assay was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition. Anticoagulated human blood samples with known concentrations of hemoglobin variant and HbA1c were analyzed. The effect of each hemoglobin variant on assay performance was evaluated comparing the mean observed %HbA1c values to the mean expected %HbA1c values. Three replicates were tested for each sample.

No significant interference bias (i.e., greater than $\pm 5 . 0 \%$ ) was observed for HbC, HbD, HbE, and HbA2. Significant interference bias was observed for HbF. Results are presented in Tables Q and R.

Table Q. Hemoglobin Variant Samples   

<table><tr><td rowspan=1 colspan=1>Hb Variant</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range (% Variant)</td><td rowspan=1 colspan=1>Range (%HbA1c)</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>26.1 - 40.0%</td><td rowspan=1 colspan=1>4.4 - 15.7%</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>22.7 - 37.5%</td><td rowspan=1 colspan=1>4.8 - 13.0%</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19.7 - 30.4%</td><td rowspan=1 colspan=1>4.7 - 11.0%</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>23.0 - 37.4%</td><td rowspan=1 colspan=1>5.3 - 13.5%</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4.3 - 6.2%</td><td rowspan=1 colspan=1>5.0 - 10.0%</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>5.7 - 30.9%</td><td rowspan=1 colspan=1>5.3 - 9.3%</td></tr></table>

Table R. Hemoglobin Variant Interference   

<table><tr><td rowspan=2 colspan=1>Hb Variant</td><td rowspan=1 colspan=2>Relative %Bias [Range of %Bias]Observed to Reference Method</td></tr><tr><td rowspan=1 colspan=1>HbA1c ~6%</td><td rowspan=1 colspan=1>HbA1c ~9%</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>0.65%[-6.17 % to 7.46%]</td><td rowspan=1 colspan=1>1.36%[-7.00% to 8.41%]</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>0.28%[-8.16 % to 6.47%]</td><td rowspan=1 colspan=1>2.27%[-1.52 % to 5.94%]</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>2.02%[-5.65 % to 7.89%]</td><td rowspan=1 colspan=1>4.35%[-1.63 % to 7.41%]</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>2.96%[-0.22 % to 6.55%]</td><td rowspan=1 colspan=1>2.51%[-2.04 % to 7.94%]</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>-1.49%[-3.87 % to 5.00%]</td><td rowspan=1 colspan=1>1.47%[-1.26 % to 6.63%]</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=2>Bias exceeds 5%</td></tr></table>

(viii) Linearity

Linearity testing was conducted CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.

A dilution series consisting of eleven (11) levels across the assay range were prepared by mixing high HbA1c and low HbA1c whole blood pools. The high pools were prepared by spiking whole blood with HbA1c. The low pools were prepared by mixing whole blood with cord blood. The expected value for each level was calculated from the measurand concentrations and volumes of the low and high samples. Three replicates were tested at each level. Samples ranged from 2.77 to $1 4 . 6 0 \%$ HbA1c.

No deviations from linearity were observed for results from 2.77 to $1 4 . 6 0 \%$ HbA1c. The regression analysis equation is Observed $\% \mathsf { H b A 1 c } = 1 . 0 0 8 8 \times$ Expected %HbA1c – 0.1110 with an ${ \mathsf { R } } ^ { 2 }$ of 0.9998.

(ix) Limit of Blank (LoB) and Limit of Detection (LoD)

Limit of Blank (LoB) and Limit of Detection (LoD) testing was conducted in accordance with CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures.

To determine LoB, four (4) blank samples were processed using three (3) reagent lots and one (1) instrument. Testing was performed for three (3) days at five (5) replicates per day for a total of 60 measurements per reagent lot (180 measurements total).

To determine LoD, four (4) low samples were processed using three (3) reagent lots and one (1) instrument. Testing was performed for three (3) days at five (5) replicates per day for a total of 60 measurements per reagent lot (180 measurements total). Results are presented in Table S.

Table S. Limit of Blank / Limit of Detection   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=1>tHb (μmol/L)</td><td rowspan=1 colspan=1>A1c (μmol/L)</td></tr><tr><td rowspan=1 colspan=1>Limit ofBlank (LoB)</td><td rowspan=1 colspan=1>3.18</td><td rowspan=1 colspan=1>60.15</td><td rowspan=1 colspan=1>1.77</td></tr><tr><td rowspan=1 colspan=1>Limit ofDetection (LoD)</td><td rowspan=1 colspan=1>3.60</td><td rowspan=1 colspan=1>69.42</td><td rowspan=1 colspan=1>2.50</td></tr></table>

# (x) Anticoagulant Comparison

Testing was performed to demonstrate equivalence between five different anticoagulants in accordance with CLSI EP09-A2, Method Comparison and Bias Estimation Using Patient Samples.

Testing was performed to demonstrate equivalence between ${ \sf K } _ { 2 }$ EDTA, ${ \sf K } _ { 3 }$ EDTA, Na Fluoride $\mathsf { N a } _ { 2 }$ EDTA, and Lithium Heparin collection tubes. HbA1c values were measured for each sample using the ADVIA A1c_E assay on the ADVIA 1800. Regression analysis was used to analyze the measured values using the ${ \sf K } _ { 2 }$ EDTA samples as the comparator. Results are presented in Tables T and U.

# SIEMENS

# Table T. Passing-Bablok Regression Analysis Summary for Anticoagulant Equivalency

Table U. Deming Regression Analysis Summary for Anticoagulant Equivalency   

<table><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>Comparator</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-intercept[95% CI]</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>1.010[1.000 to 1.018]</td><td rowspan=1 colspan=1>-0.021[-0.077 to 0.035]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/Na2-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>0.9989</td><td rowspan=1 colspan=1>0.998[0.986 to 1.005]</td><td rowspan=1 colspan=1>-0.002[-0.049 to 0.072]</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>1.025[1.016 to 1.034]</td><td rowspan=1 colspan=1>-0.096[-0.146 to -0.039]</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Anticoagulant</td><td rowspan=1 colspan=1>Comparator</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-intercept[95% CI]</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>1.011[1.000 to 1.023]</td><td rowspan=1 colspan=1>-0.034[-0.102 to 0.033]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/Na2-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>0.9989</td><td rowspan=1 colspan=1>0.996[0.986 to 1.006]</td><td rowspan=1 colspan=1>0.008[-0.045 to 0.062]</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>1.033[1.023 to 1.042]</td><td rowspan=1 colspan=1>-0.131[-0.183 to -0.079]</td></tr></table>

(xi) Conclusion

The proposed ADVIA® Chemistry Enzymatic Hemoglobin A1c (A1c_E) assay is substantially equivalent to the legally marketed predicate based on intended use, principle and the performance characteristics presented above.